RELMADA THERAPEUTICS INC (RLMD) Stock Analyst Ratings
USA - NASDAQ:RLMD - US75955J4022 - Common Stock
3.91 USD
+0.62 (+18.84%)
3.83 USD
-0.08 (-2.05%)
ChartMill assigns a Buy % Consensus number of 46% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is -73.91% below the current price.
RLMD was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-05 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-12-04 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-17 | Jefferies | Upgrade | Hold -> Buy |
| 2024-06-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2023-06-15 | Mizuho | Reiterate | Buy -> Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform |
| 2022-10-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-13 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-09-23 | Goldman Sachs | Maintains | Buy |
| 2022-09-06 | Guggenheim | Maintains | Buy |
| 2022-05-09 | Oppenheimer | Maintains | Outperform |
| 2021-12-20 | SVB Leerink | Maintains | Outperform |
| 2021-11-18 | Mizuho | Initiate | Buy |
RELMADA THERAPEUTICS INC / RLMD FAQ
What is the price target for RLMD stock?
7 analysts have analysed RLMD and the average price target is 1.02 USD. This implies a price decrease of -73.91% is expected in the next year compared to the current price of 3.91.
What is the consensus rating for RELMADA THERAPEUTICS INC (RLMD) stock?
The consensus rating for RELMADA THERAPEUTICS INC (RLMD) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.